S100 calcium binding protein A11Genealiases: HEL-S-43 · MLN70 · S100C
Q-omics provides the consensus-scored S100A11 profile across patient tissues and cancer cell-line models. S100A11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, S100A11 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, S100A11 protein abundance shows 31,490 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where S100A11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for S100A11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes S100A11 survival associations across molecular data types. S100A11 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible S100A11 RNA expression–survival associations across cancer types. High S100A11 expression shows unfavorable associations in KIRC, LUAD, UVM, LGG, KIRP and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for S100A11 RNA expression.
This table summarizes S100A11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for S100A11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. S100A11 shows higher tumor expression in COAD, KIRP, THCA, KIRC, LUSC and UCEC. The COAD box plot shows higher S100A11 RNA expression in tumor versus normal tissue (log2 FC = +2.432, t-test p < 0.001).
This table shows molecular features associated with S100A11 in patient tissues and cancer cell lines. In patient samples, S100A11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, S100A11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
